OTCMKTS:GTHP Guided Therapeutics Q3 2025 Earnings Results & Report $0.18 -0.02 (-10.00%) As of 10/9/2026 01:51 PM Eastern Guided Therapeutics reported Q3 2025 earnings on November 13, 2025. The company reported EPS of -$0.01, while revenue was $0.06 million. Research:ProfileEarnings History Earnings Announcement Details QuarterQ3 2025Report DateNovember 13, 2025TimeAfter Market Closes Guided Therapeutics EPS ResultsActual EPS-$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AGuided Therapeutics Revenue ResultsActual Revenue$0.06 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Guided Therapeutics Q3 2025 Earnings FAQ Did Guided Therapeutics beat earnings estimates for Q3 2025? Guided Therapeutics (OTCMKTS:GTHP) reported earnings of -$0.01 per share for Q3 2025. The report was announced on Thursday, November 13, 2025. What was Guided Therapeutics' revenue for Q3 2025? Guided Therapeutics reported revenue of $0.06 million for Q3 2025. Guided Therapeutics Earnings HeadlinesGuided Therapeutics Inc. (OTCMKTS:GTHP) Shares Shorted: Short Interest Up 55.0% in SeptemberOctober 1, 2026 | americanbankingnews.comGuided Therapeutics Reaches Collaborative Agreement with Türkiye’s Ministry of Health to Become Primary Screening Test for Cervical CancerSeptember 9, 2026 | finance.yahoo.comNo. 1 stock to cash in on the death of iPhoneAnalyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now. | Stansberry Research (Ad)Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese DistributorJuly 22, 2026 | finance.yahoo.comGuided Therapeutics Announces New Agreement with Distribution Partner Yuanshuo Medical Instruments CorporationJuly 14, 2026 | uk.finance.yahoo.comGuided Therapeutics Files Premarket Approval Application Clinical Report with FDAJune 16, 2026 | businesswire.comSee More Guided Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Guided Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Guided Therapeutics and other key companies, straight to your email. Email Address About Guided TherapeuticsGuided Therapeutics (OTCMKTS:GTHP), Inc. is a medical technology company focused on developing diagnostic products for women’s health. The company’s primary focus has been the detection of cervical disease and cancer using minimally invasive or non-invasive technologies. Its lead product, LuViva Advanced Cervical Scan, is designed to evaluate cervical tissue using optical spectroscopy. The system analyzes changes in tissue characteristics that may be associated with precancerous or cancerous conditions and is intended to help clinicians identify patients who may require additional evaluation, including biopsy. Guided Therapeutics has pursued regulatory and commercial opportunities for its cervical disease detection technology in the United States and international markets. The company is headquartered in Georgia and has historically focused its operations on developing, validating and commercializing diagnostic devices rather than providing direct medical care.View Guided Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
